Activity of carbapenems combined with clavulanate against murine tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2597-2600

  Veziris, Nicolas ^a,b,c   Truffot, Chantal ^a   Mainardi, Jean Luc ^a,d   Jarlier, Vincent ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Ctr Natl de Reference des Mycobacteries et de la Resistance des Mycobacteries Aux Antituberculeux   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CLAVULANIC ACID; ERTAPENEM; IMIPENEM; ISONIAZID; MEROPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; LUNG; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CARBAPENEMS; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; FEMALE; LUNG; MICE; MICROBIAL SENSITIVITY TESTS; SPLEEN; TUBERCULOSIS;

EID: 79956328683     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01824-10     Document Type: Article

References (35)

1. Beceiro, A., et al. 2009. In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii. Antimicrob. Agents Chemother. 53:4298-4304.
2. Boon, R. J., A. S. Beale, K. R. Comber, C. V. Pierce, and R. Sutherland. 1982. Distribution of amoxicillin and clavulanic acid in infected animals and efficacy against experimental infections. Antimicrob. Agents Chemother. 22:369-375.
3. Bryskier, A. 1999. Carbapénèmes, p. 305-350. In E. Paris (ed.), Antibiotiques: agents antibactériens et antifongiques. Ellipses, Marketing, Paris, France.
4. Centers for Disease Control and Prevention. 2007. Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR Morb. Mortal. Wkly. Rep. 56:250-253.
5. Centers for Disease Control and Prevention. 2009. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm. Rep. 58:1-43.
6. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
7. Chambers, H. F., et al. 1995. Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39:2620-2624.
8. Conte, J. E., Jr., J. A. Golden, M. G. Kelley, and E. Zurlinden. 2005. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int. J. Antimicrob. Agents 26:449-456.
9. EUCAST. 2010. EUCAST clinical breakpoints table, version 1.1-2010-04-27. EUCAST, Växjö, Sweden.
10. EUCAST. 2009. Ertapenem: rationale for the EUCAST clinical breakpoints, version 1.3. EUCAST, Växjö, Sweden.
11. EUCAST. 2009. Imipenem: rationale for the EUCAST clinical breakpoints, version 1.3. EUCAST, Växjö, Sweden.
12. EUCAST. 2009. Meropenem: rationale for the EUCAST clinical breakpoints, version 1.5. EUCAST, Växjö, Sweden.
13. Gandhi, N. R., et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
14. Grosset, J., and B. Ji. 1998. Experimental chemotherapy of mycobacterial diseases, p. 51-97. In P. R. Gandharam and P. Jenkins (ed.), Mycobacteria, vol. II. Marcel Dekker, New York, NY.
15. Gupta, R., et al. 2010. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16:466-469.
16. Hugonnet, J. E., and J. S. Blanchard. 2007. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 46:11998-12004.
17. Hugonnet, J. E., L. W. Tremblay, H. I. Boshoff, C. E. Barry III, and J. S. Blanchard. 2009. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323:1215-1218.
18. Jarlier, V., L. Gutmann, and H. Nikaido. 1991. Interplay of cell wall barrier and beta-lactamase activity determines high resistance to beta-lactam antibiotics in Mycobacterium chelonae. Antimicrob. Agents Chemother. 35:1937-1939.
19. Jarlier, V., and H. Nikaido. 1990. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172:1418-1423.
20. Jaruratanasirikul, S., N. Raungsri, J. Punyo, and S. Sriwiriyajan. 2005. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J. Antimicrob. Chemother. 56:1163-1165.
21. Kliiman, K., and A. Altraja. 2009. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur. Respir. J. 33:1085-1094.
22. Lavollay, M., et al. 2008. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation. J. Bacteriol. 190:4360-4366.
23. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
24. Mainardi, J. L., et al. 2007. Unexpected inhibition of peptidoglycan L,Dtranspeptidase from Enterococcus faecium by the beta-lactam imipenem. J. Biol. Chem. 282:30414-30422.
25. Mattie, H., L. C. Zhang, E. van Strijen, B. R. Sekh, and A. E. Douwes-Idema. 1997. Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection. Antimicrob. Agents Chemother. 41:2083-2088.
26. Nix, D. E., A. K. Majumdar, and M. J. DiNubile. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. 53(Suppl. 2):ii23-ii28.
27. Payen, M., C. Martin, T. Antoine-Moussiaux, S. De Wit, and N. Clumeck. 2010. Four cases of XDR-tuberculosis treated with meropenem-clavulanate. 50th Intersci. Conf. Antimicrob. Agents Chemother.
28. Poissy, J., et al. 2010. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob. Agents Chemother. 54:4765-4771.
29. Stearne, L. E., S. L. Buijk, J. W. Mouton, and I. C. Gyssens. 2002. Effect of a single percutaneous abscess drainage puncture and imipenem therapy, alone or in combination, in treatment of mixed-infection abscesses in mice. Antimicrob. Agents Chemother. 46:3712-3718.
30. Veziris, N., N. Lounis, A. Chauffour, C. Truffot-Pernot, and V. Jarlier. 2005. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 49:4015-4019.
31. Veziris, N., et al. 2007. Treatment failure in a case of extensively drugresistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. Eur. J. Clin. Microbiol. Infect. Dis. 26:423-425.
32. World Health Organization. 2010. Global tuberculosis control: a short update to the 2009 report. World Health Organization, Geneva, Switzerland.
33. World Health Organization. 2006. Global tuberculosis control: surveillance, planning, financing. WHO report 2006: WHO/HTM/TB/2006.362. World Health Organization, Geneva, Switzerland.
34. Xuan, D., et al. 2002. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. 46:2990-2995.
35. Zignol, M., et al. 2006. Global incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 194:479-485.